MX2021015776A - Composiciones farmaceuticas en la forma de gel que contienen xiloglucano y alcoholes para la liberacion controlada de principios activos. - Google Patents

Composiciones farmaceuticas en la forma de gel que contienen xiloglucano y alcoholes para la liberacion controlada de principios activos.

Info

Publication number
MX2021015776A
MX2021015776A MX2021015776A MX2021015776A MX2021015776A MX 2021015776 A MX2021015776 A MX 2021015776A MX 2021015776 A MX2021015776 A MX 2021015776A MX 2021015776 A MX2021015776 A MX 2021015776A MX 2021015776 A MX2021015776 A MX 2021015776A
Authority
MX
Mexico
Prior art keywords
controlled release
active ingredients
alcohols
pharmaceutical compositions
gel containing
Prior art date
Application number
MX2021015776A
Other languages
English (en)
Inventor
Clelia Dispenza
Giuseppe Claudio Viscomi
Paola Maffei
Cristiana Bruno
Mascia Federici
Maria Antonietta Sabatino
Original Assignee
Alfasigma Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alfasigma Spa filed Critical Alfasigma Spa
Publication of MX2021015776A publication Critical patent/MX2021015776A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)

Abstract

La invención se refiere a composiciones en gel que comprenden principios activos farmacéuticos; la composición comprende xiloglucano a una concentración entre 0.1% y 10.0% en peso total de la composición, junto con un alcohol a una concentración entre 5.0 y 50.0% en peso total de la composición; la invención también describe un procedimiento para la preparación de la composición y su uso en el tratamiento de patologías en donde es útil una liberación controlada del principio activo.
MX2021015776A 2019-06-21 2020-06-11 Composiciones farmaceuticas en la forma de gel que contienen xiloglucano y alcoholes para la liberacion controlada de principios activos. MX2021015776A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT201900009273 2019-06-21
PCT/EP2020/066181 WO2020254179A1 (en) 2019-06-21 2020-06-11 Pharmaceutical compositions in the form of gel containing xyloglucan and alcohols for the controlled release of active ingredients

Publications (1)

Publication Number Publication Date
MX2021015776A true MX2021015776A (es) 2022-01-31

Family

ID=68582095

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021015776A MX2021015776A (es) 2019-06-21 2020-06-11 Composiciones farmaceuticas en la forma de gel que contienen xiloglucano y alcoholes para la liberacion controlada de principios activos.

Country Status (7)

Country Link
US (1) US20220241193A1 (es)
EP (1) EP3986378A1 (es)
JP (1) JP2022537460A (es)
CN (1) CN114096237A (es)
EA (1) EA202290122A1 (es)
MX (1) MX2021015776A (es)
WO (1) WO2020254179A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115569110B (zh) * 2022-10-18 2023-04-28 杨伊森(广州)生命科学技术有限公司 重组iii型胶原水凝胶组合物、制备方法及应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6432449B1 (en) 1998-05-18 2002-08-13 Amgen Inc. Biodegradable sustained-release alginate gels
JP2002003398A (ja) 2000-04-17 2002-01-09 Ltt Institute Co Ltd 徐放製剤、その製造法及びワクチン
ITMI20031640A1 (it) * 2003-08-08 2005-02-09 Mipharm S P A Base per gel bioadesivi.
ITBO20050388A1 (it) * 2005-06-06 2006-12-07 Alfa Wassermann Spa Formulazione mucoadesive utili in dispositivi medici in preparazioni farmaceutiche
KR100813224B1 (ko) 2007-08-24 2008-03-13 한양대학교 산학협력단 단백질 약물전달용 온도 가역성 코아세르베이트 조합 겔
JP5575798B2 (ja) * 2008-12-15 2014-08-20 カウンシル オブ サイエンティフィック アンド インダストリアル リサーチ 透明キシログルカン／キトサンゲル及びその製造方法
ITBO20110461A1 (it) * 2011-07-29 2013-01-30 Alfa Wassermann Spa Composizioni farmaceutiche comprendenti rifaximina, processi per la loro preparazione e loro uso nel trattamento di infezioni vaginali.
EP3173067B1 (en) 2015-11-16 2018-11-14 Istanbul Universitesi Rektorlugu Mucoadhesive buccal in situ gel formulation
JP6490134B2 (ja) * 2017-04-05 2019-03-27 Ｄｓｐ五協フード＆ケミカル株式会社 キシログルカン含有ゲル状組成物

Also Published As

Publication number Publication date
EA202290122A1 (ru) 2022-03-17
US20220241193A1 (en) 2022-08-04
CN114096237A (zh) 2022-02-25
WO2020254179A1 (en) 2020-12-24
JP2022537460A (ja) 2022-08-25
EP3986378A1 (en) 2022-04-27

Similar Documents

Publication Publication Date Title
ECSP19030002A (es) 1,2,4-triazolonas 2,4,5-trisustituidas
MX2022014313A (es) Formulaciones para administracion oral de agentes activos con perfil de absorcion controlada.
HUP0303879A2 (hu) Zsíralkohol-etoxilátok alkalmazása penetrációt elősegítő szerként
ECSP22041839A (es) Aminoquinolonas sustituidas como inhibidores de dgk alfa para la activación inmune
MX2011011459A (es) Formulacion de clavulanato para neuroproteccion y tratamiento de trastornos neurodegenerativos.
CR20210686A (es) Análogos de 3–(5–metil–1,3–tiazol–2–il)–n–{(1r)–1–[2–(trifluor–metil)pirimidin–5–il]etil}benzamida
WO2015081904A3 (en) Polyurethaneurea solutions for compositions with active ingredients or fragrances
CR20220278A (es) Derivados de 3-(5-metoxi-1-oxoisoindolin-2-il)piperidin-2,6-diona y usos de los mismos
WO2021046315A3 (en) Inhibitors of encephalitic alphaviruses
KR102272901B1 (ko) 메조-2,3-부탄디올을 방부제로서 함유하는 피부 외용제 조성물
MX2021015776A (es) Composiciones farmaceuticas en la forma de gel que contienen xiloglucano y alcoholes para la liberacion controlada de principios activos.
JP2020164548A (ja) メゾ−２，３−ブタンジオールを含有する組成物
IN2014MN00929A (es)
WO2010041908A3 (ko) 판두라틴 유도체 또는 보에센베르기아 판두라타 추출물의 신규한 용도
MX2016008546A (es) Reduccion de queloides utilizando alantoina topica.
ZA202200331B (en) Naltrexone formulation
WO2021161023A8 (en) Compounds useful in inhibiting ketohexokinase and methods of making and using the same
JP6971570B2 (ja) 花粉破裂抑制剤
MX2021015732A (es) Administracion intranasal de merotocina para mejorar la lactancia.
MX349868B (es) Composiciones de gel.
MX2021014425A (es) Composicion para el cuidado bucal.
JP6940276B2 (ja) 花粉破裂抑制剤
MX2017013265A (es) Composicion para formulacion cosmetica humectante de larga duracion que comprende manteca de ucuuba con altas concentraciones de acido miristico asi como el uso de la formulacion para la preparacion de un producto cosmetico altamente humectante y kit.
MX2020011323A (es) Composicion farmaceutica para liberacion controlada de treprostinil.
AU2019203288A1 (en) Process for preparing pharmaceutical compositions resulting in reduction in overall fill volume for use with soft gelatin formulations